Clinical Scorecard: Berberine Mitigates Immune-Inflammatory Damage Associated with Biofilms in Osteomyelitis Induced by Staphylococcus aureus: Findings from Experimental Validation and Network Pharmacology Analysis
At a Glance
Category
Detail
Condition
Osteomyelitis induced by Staphylococcus aureus
Key Mechanisms
Antibacterial and anti-inflammatory activities of Berberine; disruption of biofilm formation
Target Population
Patients with osteomyelitis caused by Staphylococcus aureus
Care Setting
Orthopedic infection management
Key Highlights
Berberine significantly reduced bacterial viability within biofilms.
In vivo studies showed BBR alleviated bone destruction and reduced inflammatory cell infiltration.
Network pharmacology identified PTGS2 as a key target for BBR.
BBR's antibacterial efficacy was weaker than that of clindamycin.
BBR should be considered as an adjunctive therapy for biofilm-associated osteomyelitis.
Guideline-Based Recommendations
Diagnosis
Diagnosis of osteomyelitis should consider the presence of Staphylococcus aureus and biofilm formation.
Management
Berberine may be used as an adjunctive therapy alongside standard antibiotic treatment.
Monitoring & Follow-up
Monitor inflammatory mediator levels and bone healing in patients treated with Berberine.
Risks
BBR should not replace antibiotics due to its lower antibacterial efficacy.
Patient & Prescribing Data
Patients with chronic osteomyelitis due to Staphylococcus aureus.
Berberine can reduce inflammation and biofilm formation but is less effective than clindamycin.
Clinical Best Practices
Combine Berberine with antibiotics for enhanced treatment of biofilm-associated infections.
Utilize network pharmacology to identify potential therapeutic targets in osteomyelitis.
